I had called the company regarding note 7 some time ago. This is an old case. The High Court has already ruled in their favour and the company seems confident that even the Supreme court should do the same. The company is tiding over this issue with the NPPA.
Annual growth rate has been impressive from 2014 to 2015. The EPS has grown in excess of 20%.
I have also spoken to many (cannot remember the number also) pharmacists in Mumbai…they all say that Jenburkt Pharmas products are very well accepted by Doctors and Patients. The company enjoys a very good name in the market.
I suggest you visit 5-10 pharmacies in your locality (if in mumbai) and ask for the quality of Jenburkts medicines.
To conclude, I believe the company will continue to grow at 20% for quite a few years just as it has done in the past. They will remain debt free. Enjoy extremely high ROIC and continue to pay impressive dividend (12rs+ in FY15).
This is a compounder.